ASPHALION SL

Their core work

Asphalion is a Barcelona-based regulatory affairs and consulting firm specialized in life sciences, providing regulatory strategy, preclinical/clinical development support, and compliance services for advanced therapies including gene therapy, cell therapy, and medical devices. In H2020 consortia, they serve as the regulatory and quality assurance partner, helping research teams navigate EU regulatory pathways (EMA, notified bodies) to translate lab-stage innovations into approved therapies and products. Their consistent presence across 13 health and biotech projects — always as a specialist contributor — indicates a focused service role bridging research and market authorization. They bring deep knowledge of advanced therapy medicinal products (ATMPs), in vitro/in vivo testing requirements, and biocompatibility standards.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Asphalion supported a broad range of biomedical projects — from HIV vaccines and musculoskeletal nanoparticles to cardiovascular gene therapy and diabetes cell therapy — establishing themselves as a versatile regulatory partner for diverse therapeutic areas. From 2019 onward, their portfolio sharpened around advanced therapies (gene therapy, cell therapy, rare diseases) and emerging bioengineering technologies (organ-on-chip, bioprinting, in vivo optical imaging), reflecting the industry's shift toward ATMPs and personalized medicine. This evolution suggests they have built specialized regulatory expertise precisely where the European Medicines Agency is developing new frameworks.

Asphalion is deepening its expertise in regulatory pathways for ATMPs, bioprinting, and organ-on-chip technologies — positioning them as the go-to regulatory partner for next-generation therapeutic products entering EU markets.

How they like to work

Asphalion operates exclusively as a specialist partner, having participated in all 13 projects without coordinating any — a clear indicator of a service-oriented role rather than a research-driving one. With 150 unique consortium partners across 23 countries, they work comfortably in large, multi-national research consortia and appear to be sought after for their specific regulatory competence rather than building long-term exclusive partnerships. For potential collaborators, this means they are experienced at integrating into diverse teams, delivering defined work packages on regulatory strategy, and working across cultural and institutional boundaries.

Asphalion has built an extensive European network spanning 150 unique partners across 23 countries, reflecting their role as a sought-after regulatory specialist embedded in major health research consortia. Their Barcelona base gives them strong connections to Southern European research institutions, but their reach is clearly pan-European.

What sets them apart

Asphalion fills a critical gap that most research consortia struggle with: translating promising science into regulatory-compliant products. While universities and research institutes drive the science, Asphalion provides the regulatory intelligence needed to design studies that satisfy EMA requirements from the start, avoiding costly redesigns later. Their track record across gene therapy, cell therapy, bioprinting, and medical devices makes them one of the few SMEs that can handle regulatory strategy for truly experimental therapeutic categories where no established pathway exists.

Highlights from their portfolio

• ARDAT
  Their largest funded project (EUR 352,500), focused on accelerating advanced therapy development — directly aligned with their core regulatory mission.
• VASCOVID
  A rapid-response COVID-19 project developing bedside ICU monitoring — demonstrates their ability to support urgent medical device development under compressed timelines.
• Tumor-LN-oC
  Combines organ-on-chip, bioprinting, and microfluidics — represents the frontier of regulatory challenges where no established frameworks exist yet.